uniQure Shares Plunge After Huntington's Therapy Data Misses Key Statistical Endpoint

Shares of gene therapy developer uniQure N.V. (NASDAQ: QURE) plummeted by as much as 64% in trading on Tuesday after the company released an updated 48-month data analysis for its experimental Huntington’s disease treatment, ifezuntirgene inilparvovec (AMT-130). The massive sell-off was triggered by the therapy's failure to achieve statistical significance on a key composite endpoint, a critical setback in the eyes of investors.

The 48-Month Data Disappointment

The market's reaction centered on results from 12 high-dose patients. While the treatment showed a 44% slowing of disease progression compared to a control group on the composite Unified Huntington’s Disease Rating Scale (cUHDRS), this finding was not statistically significant, with a p-value of 0.144.

In biotechnology development, a p-value above the typical threshold of 0.05 on a major endpoint is often viewed as a failure, indicating that the observed effect could be due to chance. uniQure attributed the statistical miss to a "survivor bias" in its external control group, where a 53% patient dropout rate by month 48 left a healthier-than-average cohort for comparison.

Regulatory Path and Positive Signals

Despite the market's negative reaction, uniQure's regulatory strategy may remain largely intact. The company stated that the U.S. Food and Drug Administration (FDA) previously agreed that the 36-month data would be the primary basis for its Biologics License Application (BLA), which has already been submitted for accelerated approval.

Ad

The updated 36-month analysis for 15 high-dose patients remains robust, showing an 80% slowing of disease progression on the cUHDRS (p=0.005) and a 67% slowing on Total Functional Capacity (p=0.011). These highly significant results form the core of the company's submission to regulators.

Underlying Efficacy and Safety

Beyond the headline miss, the 48-month data contained several encouraging signs. On the crucial metric of Total Functional Capacity (TFC), which measures a patient's ability to perform daily activities, the high-dose group showed a 61% slowing of functional decline, a result that was statistically significant (p=0.008).

The data also continued to demonstrate a clear dose-dependent response, with high-dose patients showing better outcomes than low-dose patients, which supports the drug's therapeutic effect. The treatment's safety profile was described as generally manageable, though five high-dose participants experienced serious adverse events involving brain inflammation, all of which resolved.